EPHB2 and hepatocellular carcinoma: Additionally, in patients with hepatocellular carcinoma, the overexpression of ASL may give rise to drug resistance against arginine deprivation therapy [44], while targeting a positive feedback loop involving EPHB2 may be a promising therapeutic strategy to combat cancer stemness and sorafenib resistance [45].